{"id":65649,"date":"2026-05-19T19:34:44","date_gmt":"2026-05-19T11:34:44","guid":{"rendered":"https:\/\/flcube.com\/?p=65649"},"modified":"2026-05-19T19:34:45","modified_gmt":"2026-05-19T11:34:45","slug":"accro-bioscience-secures-50m-series-c-to-advance-ripk2-inhibitor-ac-101-into-phase-iib-ulcerative-colitis-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65649","title":{"rendered":"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial"},"content":{"rendered":"\n<p><strong>Accro Bioscience (Suzhou) Limited<\/strong> announced the completion of a <strong>$50 million Series C financing round<\/strong>, led by <strong>OrbiMed<\/strong> with participation from <strong>TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital<\/strong>, and existing shareholders <strong>Shenzhen Capital Group (SCGC)<\/strong> and <strong>Oriza Holdings<\/strong>. The funding will accelerate the company&#8217;s lead asset, <strong>AC-101<\/strong>, a <strong>global-leading RIPK2 inhibitor<\/strong>, into a <strong>Phase IIb clinical trial for ulcerative colitis (UC)<\/strong>, while advancing multiple pipeline candidates for inflammatory and immune diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-details-amp-investor-syndicate\">Financing Details &amp; Investor Syndicate<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Round<\/strong><\/td><td>Series C<\/td><\/tr><tr><td><strong>Amount Raised<\/strong><\/td><td>$50 million<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>OrbiMed<\/td><\/tr><tr><td><strong>New Investors<\/strong><\/td><td>TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital<\/td><\/tr><tr><td><strong>Existing Investors<\/strong><\/td><td>Shenzhen Capital Group (SCGC), Oriza Holdings<\/td><\/tr><tr><td><strong>Strategic Significance<\/strong><\/td><td>Strong validation from both global healthcare specialists (OrbiMed, LAV) and crossover investors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-asset-ac-101-clinical-development\">Lead Asset: AC-101 Clinical Development<\/h2>\n\n\n\n<p><strong>AC-101<\/strong> represents a <strong>novel, selective RIPK2 inhibitor<\/strong> developed from Accro&#8217;s proprietary drug discovery platform targeting regulated cell death pathways:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Selective inhibition of <strong>Receptor-interacting protein kinase 2 (RIPK2)<\/strong>, a key mediator of the <strong>NOD signaling pathway<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Dysregulation of the <strong>NOD\u2013RIPK2 pathway<\/strong> is implicated in various autoimmune diseases, particularly <strong>inflammatory bowel disease (IBD)<\/strong><\/li>\n\n\n\n<li><strong>Clinical Progress<\/strong>:<\/li>\n\n\n\n<li><strong>Phase I trials<\/strong> completed in Australia and China with <strong>favorable safety profile<\/strong> and <strong>strong PK\/PD data<\/strong><\/li>\n\n\n\n<li><strong>Phase Ib\/IIa proof-of-concept trial<\/strong> completed in Chinese patients with <strong>moderate-to-severe UC<\/strong><\/li>\n\n\n\n<li><strong>US regulatory clearance<\/strong> obtained for Phase II clinical study in ulcerative colitis<\/li>\n\n\n\n<li><strong>Next Milestone<\/strong>: <strong>Phase IIb global trial<\/strong> initiation expected in Q3 2026<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-expansion-strategy\">Pipeline Expansion Strategy<\/h2>\n\n\n\n<p>Beyond AC-101, the financing will support development of <strong>multiple additional pipeline assets<\/strong> targeting inflammatory and immune diseases, leveraging Accro&#8217;s proprietary platform for regulated cell death modulation. This diversified approach reduces single-asset risk while capitalizing on validated target biology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ulcerative Colitis Market<\/strong>: Global UC therapeutics market projected to reach $12.8 billion by 2030, with significant unmet need for safer, more effective oral therapies<\/li>\n\n\n\n<li><strong>RIPK2 Target Validation<\/strong>: Emerging as a high-priority target in IBD, with multiple pharma companies pursuing RIPK2 inhibitors but Accro positioned as potential first-to-market<\/li>\n\n\n\n<li><strong>Differentiation Advantage<\/strong>: AC-101&#8217;s selectivity profile may offer improved safety compared to broader kinase inhibitors, addressing key limitations of current UC therapies<\/li>\n\n\n\n<li><strong>China Innovation Ecosystem<\/strong>: Accro exemplifies the maturation of China&#8217;s biotech sector, with domestic innovation achieving global competitive positioning in specialized therapeutic areas<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-investor-alignment\">Strategic Investor Alignment<\/h2>\n\n\n\n<p>The investor consortium brings complementary strategic value:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>OrbiMed<\/strong>: Global healthcare expertise and regulatory guidance for US\/EU development<\/li>\n\n\n\n<li><strong>Lilly Asia Ventures<\/strong>: Potential partnership opportunities with Eli Lilly&#8217;s immunology franchise<\/li>\n\n\n\n<li><strong>TCG Crossover<\/strong>: Public market preparation and valuation expertise<\/li>\n\n\n\n<li><strong>Chinese Institutional Investors<\/strong>: Local market access and operational support<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market opportunities for AC-101 and Accro&#8217;s pipeline. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2788],"class_list":["post-65649","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-accro-bioscience"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round, led by OrbiMed with participation from TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital, and existing shareholders Shenzhen Capital Group (SCGC) and Oriza Holdings. The funding will accelerate the company&#039;s lead asset, AC-101, a global-leading RIPK2 inhibitor, into a Phase IIb clinical trial for ulcerative colitis (UC), while advancing multiple pipeline candidates for inflammatory and immune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65649\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial\" \/>\n<meta property=\"og:description\" content=\"Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round, led by OrbiMed with participation from TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital, and existing shareholders Shenzhen Capital Group (SCGC) and Oriza Holdings. The funding will accelerate the company&#039;s lead asset, AC-101, a global-leading RIPK2 inhibitor, into a Phase IIb clinical trial for ulcerative colitis (UC), while advancing multiple pipeline candidates for inflammatory and immune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65649\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T11:34:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T11:34:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65649#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65649\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial\",\"datePublished\":\"2026-05-19T11:34:44+00:00\",\"dateModified\":\"2026-05-19T11:34:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65649\"},\"wordCount\":482,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Accro Bioscience\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65649#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65649\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65649\",\"name\":\"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-19T11:34:44+00:00\",\"dateModified\":\"2026-05-19T11:34:45+00:00\",\"description\":\"Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round, led by OrbiMed with participation from TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital, and existing shareholders Shenzhen Capital Group (SCGC) and Oriza Holdings. The funding will accelerate the company's lead asset, AC-101, a global-leading RIPK2 inhibitor, into a Phase IIb clinical trial for ulcerative colitis (UC), while advancing multiple pipeline candidates for inflammatory and immune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65649#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65649\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65649#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round, led by OrbiMed with participation from TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital, and existing shareholders Shenzhen Capital Group (SCGC) and Oriza Holdings. The funding will accelerate the company's lead asset, AC-101, a global-leading RIPK2 inhibitor, into a Phase IIb clinical trial for ulcerative colitis (UC), while advancing multiple pipeline candidates for inflammatory and immune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65649","og_locale":"en_US","og_type":"article","og_title":"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial","og_description":"Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round, led by OrbiMed with participation from TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital, and existing shareholders Shenzhen Capital Group (SCGC) and Oriza Holdings. The funding will accelerate the company's lead asset, AC-101, a global-leading RIPK2 inhibitor, into a Phase IIb clinical trial for ulcerative colitis (UC), while advancing multiple pipeline candidates for inflammatory and immune diseases.","og_url":"https:\/\/flcube.com\/?p=65649","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T11:34:44+00:00","article_modified_time":"2026-05-19T11:34:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65649#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65649"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial","datePublished":"2026-05-19T11:34:44+00:00","dateModified":"2026-05-19T11:34:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65649"},"wordCount":482,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Accro Bioscience"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65649#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65649","url":"https:\/\/flcube.com\/?p=65649","name":"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-19T11:34:44+00:00","dateModified":"2026-05-19T11:34:45+00:00","description":"Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round, led by OrbiMed with participation from TCG Crossover, Lilly Asia Ventures (LAV), Centurium Capital, and existing shareholders Shenzhen Capital Group (SCGC) and Oriza Holdings. The funding will accelerate the company's lead asset, AC-101, a global-leading RIPK2 inhibitor, into a Phase IIb clinical trial for ulcerative colitis (UC), while advancing multiple pipeline candidates for inflammatory and immune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65649#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65649"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65649#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65649"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65649\/revisions"}],"predecessor-version":[{"id":65650,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65649\/revisions\/65650"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}